The signs of septicaemia in the newborn are very non-specific, yet treatment must be prompt and effective in order to save the patient. It is now standard practice to treat neonates with more than one antibiotic at the first suspicion of infection. The infecting organisms are very often of nosocomial origin and Gram negative wrobic rods predominate. An outbreak of septicaemia caused by multi-resistant Klebsiella species in the University Children's Hospital, Munich in 1972-73 led to the withdrawal of ampicillin and, shortly afterwards, of gentamicin also when a high rate of resistance emerged. Since then, a different aminoglycoside together with a cephalosporin' such as cephalothin have been used parenterally at the first sign of sepsis and acute drug toxicity has not been seen.
Poor cerebrospinal fluid (CSF) penetration is a serious disadvantage of both these antibiotics, however, and so we were pleased to have an opportunity of evaluating cefuroxime in children and in neonates. We first examined the in vitro activity of cefuroxime in comparison with cephalothin against 251 recent clinical isolates of Gram negative organisms (Table 1) , measuring the minimal inhibitory concentrations (MICs) by broth dilution in microtitre trays and using an inoculum of 108_109 colony forming units/well. If strains with an MIC of 16 or less are regarded as sensitive, then the superiority of cefuroxime over cephalothin against the 2 most common isolates (Escherichia coli and Klebsiella spp.) is plain, and we regarded this as a clear indication to change to cefuroxime (or another equivalent
Patienits and Methods
We treated 26 neonates with proven or suspected sepsis, I infant aged 3 months and a child aged 12 years with cefuroxime in a dose of 100 mg/kg/ day for 3-18 days. Eight children were treated for less than 5 days and the mean duration of treatment was 7.1 days. All patients but one were treated with additional antibiotics as shown in Table 2 .
The indications for treatment were septicemia in 3 cases, 2 of whom also had meningitis; chest infection in 2 cases and suspected neonatal sepsis in 23 cases. Blood cultures were collected from all patients before starting and at intervals during and after treatment.
RESULTS

Clinzical Response
Of the 3 patients with positive blood cultures, 2 (Kiebsiella MIC 2 mg/l and Escherichia coli, MIC not available) improved and had negative cultures on follow up. The latter patient, who was treated for 11 days and received additional tobramycin and carbenicillin, relapsed clinically 5 days later and was further treated with amikacin and cephalothin. Blood and CSF cultures remained sterile, however. The third patient, a 13-week-old baby with Escherichia coli meningitis (MfC-0.5 mg/l) was treated with cefuroxime alone, but changed to chloramphenicol after the third dose Table 2 Multiple therapy using cefuroxime in children papular rash for which we did not stop treatment, and another with eosinophilia, no side effects or 2.8 kg changes in hamatological or biochemical parameters attributable to thie drug were seen.
Drug Concentrations
Blood concentration curves were measured after the initial dose and, in some patients, on the fourth and seventh days of therapy. Capillary G. 4d samples were collected from heel-prick, separated, diluted 1:10 to 1:40 in phosphate buffer, pH 7.0, 3.0 kg and assayed by the agar well-plate diffusion 90 method using Oxoid Antibiotic Medium No. 2, min pH 7.0, with added sodium citrate (3 g/l) and ildose Bacillus subtilis 1904E (Glaxo Research Ltd) as test organism. We thought at first that the presence of an aminoglycoside in the samples would interfere with the assay and the data relating to the initial dose were obtained before the aminoglycoside was given. ft was later found in carefully controlled experiments that there was no interference with zone size by the presence of 'K.5d the very small quantities of amikacin found at the high dilutions used in this assay system, and so blood concentration curves during therapy could also be measured in patients receiving additional amikacin. All blood samples were of capillary blood obtained by heel-prick. Serum concentration curves after the initial dose (Fig 1) were constructed in 4 patients, all with suspected sepsis. The individual variation in peak levels is considerable. Patients W, K and G were all full-term or nearly full-term neonates aged 1-4 days and all showed serum half-lives of 3-4 h or longer. Patient B, on the other hand, was 23 days old, although born prematurely (weight 1.76 kg), and had a half-life of approximately I h. The unusual pattern of increase after an i.v. dose of the curves for K and G may well be due to subcutaneous leakage around the i.v. cannula, or to inaccurate estimation by the nurse concerned of the moment when the dose introduced into the cannula tubing had reached the vein.
In the light of these initial dose curves, we studied serum concentrations over the 8 h period after the initial dose and also, on subsequent days during therapy (Fig 2) . Patients A, K and S are similar; no initial dose data are available for patient Z. These curves confirm the long halflives in the newborn, but demonstrate nevertheless that the drug is adequately excreted.
We were able to assay CSF cefuroxime concentrations in 2 patients, the one with Escherichia coli meningitis who had a level of 20 mg/l after the third dose, and the other with gross hydrocephalus whose CSF concentrations were 50.2 mg/I, 2.5 h after an i.v. dose on day 4 of treatment, and 47.3 mg/l 3 h after a dose on day 7. The presence of carbenicillin in a further patient with Escherichia coli meningitis prevented our assaying cefuroxime in his CSF. The high levels in the hydrocephalic may well be attributable to abnormalities in the blood-brain barrier.
Conclutsions
Cefuroxime in a high i.v. dose is well tolerated in the neonate even when normal doses of aminoglycosides are given at the same time. The immaturity of renal and other vital functions in the first few days of life, however, results in considerable and irregular prolongation of the serum half-life. Our data so far have not shown a tendency to accumulate, but further studies, particularly from premature babies, are urgently needed to elucidate this point. Acknowledgments P J Wilkinson was in receipt of a Humboldt Foundation Research Fellowship during the pericd of this research. DISCUSSION Professor Kouvalainen (Chairman) said that it was well known that the kinetics and metabolism of drugs in infants and newborns differed in many respects from that in adults. He suggested that attention first be focused on the kinetics and dosage of cefuroxime in newborn and older children.
Professor H C Neu (New York) said that in one of Dr Renlund's studies it was not clear whether the patient in whom he had measured CSF levels had received any other antibiotic and whether there was any question of competition for transport.
Dr Renlund said that the patient had not, and there was no such question.
Professor C Simon (Kiel) had investigated the pharmacokinetics of cefazolin in newborns and premature babies at a dosage of 60 mg/kg. At a dosage interval of 12 h, peak and trough levels were no higher than in adults at this dosage. Because distribution volumes were greater, there was no danger of accumulation at a dosage of 60-100 mg/kg/day. In severe infections, particularly where unknown organisms were involved, it was safer to combine the treatment with an aminoglycoside.
Dr J 0 Klein (Boston) said that data from Dr Renlund and Dr Wilkinson on the penetration of drug into CSF in children with meningitis was very encouraging. However, the child presented by Dr Renlund with meningitis on the 6th day of cefuroxime therapy was somewhat disconcerting. He asked if the child was initially bactereemic with Staphylococcus and if the organism had a high MIC.
Dr Renlund confirmed that Staphylococcus had been isolated from the CSF on the sixth day of therapy. They suspected the child had a septicexmia. It was found to have high levels of leucocytes in the CSF. Accordingly, they changed the drug.
Professor H C Neu (New York) said that 2 investigators had used widely differing doses, 10 mg/kg.and 100 mg/kg. Both showed half-lives of 3 h and he asked what they considered the correct dose; whether for the first week it should be given 12 hourly and at what point it should be switched to 8 hourly intervals.
Dr Wilkinson said that experience of outbreaks of infection in the last 5 years in which a number of babies had died had dictated Professor Marget's policy of using antibiotics in specific cases at relatively high doses in an attempt to ensure adequate treatment.
On the basis of pharmacokinetic data, a level of 100 mg/kg might be somewhat high, but he nonetheless favoured regular doses approaching that level. Because of the prolonged half-life of the drug in the early days of life, he advocated 12 hourly doses up to 4 days of age, increasing to 8 h subsequently. However, it was very difficult to know how the half-life would change without adequate laboratory investigation. It was therefore difficult to produce any general statement which would be safe as well as adequate.
He further noted that Dr Renlund's patients were receiving 10 mg/kg/day three times daily, or 30 mg/kg/day in total. His own patients were receiving 33 mg/kg/dose every 8 h.
Dr Renlund had gained the impression that for the first 3 days it was sufficient to give the dose twice daily. After that, a three times daily regime was preferred, and French investigations suggested that the half-life probably decreased rapidly after some months.
Professor C S Goodwin (Perth) was encouraged by results obtained with 33 mg/kg/dose. ff this could be given safely, he felt it wise to give such a dose to children who were ill and in whom it was necessary for the drug to enter the CSF. In the i.v. studies, no toxicity was apparently seen.
Professor Kouvalainen said that a dose level of 100 mg/kg/day in a baby was comparable to a level of 10 g/day in an adult. He did not think it desirable to exceed the dose which seemed optimal from the bacteriological point of view and he asked what was the optimal level of cefuroxime in neonatal blood.
Professor C Simon (Kiel) said that adult doses of 3-4 g daily corresponded to 45-65 mg/kg/day in newborns and infants. With cefazolin, 60 mg/kg/ day in newborns gave peak and trough levels comparable to those in the adult. He believed that with the exception of a longer interval in the early days, there was no important difference in dosage between the newborn and the adult.
Professor Kouvainen (Chairman) did not fully agree. In the first week of life there were unusual pharmacological responses. If Professor Pettay and Dr Renlund had favourable results with 10 mg/kg in prematurely born babies, he questioned the wisdom of giving 100 mg/kg. Professor Pettay said they had started with small doses which gave serum concentrations of 20-25 )ug/ml, levels that were effective in most adult infections. It was true that to obtain an effective concentration in CSF it was necessary to increase the dosage, but he did not think that they would triple the dose they were currently using.
Professor H C Neu (New York) said that at serum levels of 20 ,ug/ml, if the CSF level was only 15-25%, many of the E. coli that would be a major cause of meningitis would have an MIC and an MBC in excess of that concentration. Using cefuroxime to treat an ampicillin resistant E. coli sepsis and meningitis it might be necessary to go to a higher dose level in order to achieve an MBC of 6-10 fig/ml. Professor C S Goodwin (Perth) said that a wide range of serum concentrations had been achieved with similar doses. He felt it more valuable to concentrate on the level given at 12 hourly intervals in the first week of life and then 8 hourly, rather than on the total daily dose. Certainly in meningitis, the absence of toxicity encouraged the use of the i.v. route.
Mr A J Bron (Oxford) asked if information existed on differences in concentration in the ventricular as opposed to the spinal space; whether there were data on gradients ofconcentration along the sub-arachnoid space and whether the CSF level obtained from spinal fluid really represented the concentration at all levels in the sub-arachnoid space. Dr Wilkinson said that 2 of the patients in whom they had measured levels were hydrocephalic and the fluid had been withdrawn by ventricular puncture. In the other it had been withdrawn from the lower lumbar space. This was an interesting question but it was extraordinarily difficult to obtain the data in patients in this age group.
He accepted Mr Bron's suggestion of serial tap samples as the ideal, but the practical difficulties were sometimes overwhelming.
Miss NI R K Kennedy (Gree,dford) asked Dr Sorin how he had assayed cefuroxime in the presence of gentamicin.
Dr Sorin said they used a plate diffusion method with an organism resistant to gentamicin.
Dr P W Muoggleton (Greenford) asked Dr Sorin for more details of the case of Staphylococcus aur-eus infection which was unsuccessful.
Dr Sorin said that the patient was a child with pleuropulmonary Staphylococcal infection. After 48 h he still had signs of infection and the antibiotic treatment was stopped. They did not determine the MIC, but a disc method had shown the organism to be resistant.
Professor Kouvalainen (Chairman) said it seemed that the half life of cefuroxime in newborns during the first week, and perhaps the first month of life, was 3-6 times that in the adult. However, as Dr Simon had observed, the large 187 distribution volume compensated and therefore the clearance of cefuroxime was not as greatly disturbed as those figures might suggest. However, careful study was still needed to determine the optimal dosage in newborns. He guessed that at some weeks of age it might be possible to discount this longer half-life effect, as data from Dr Sorin and Dr Renlund had suggested.
